BioCentury
ARTICLE | Clinical News

Galapagos reports Phase II CF data for GLPG2222 combo

November 30, 2017 11:27 PM UTC

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The double-blind, international trial enrolled 37 CF patients on long-term stable treatment with Kalydeco who had a delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation and a gating mutation.

Galapagos said the data will inform dose selection for a triple combination trial that is expected to start this quarter. The trial will evaluate GLPG2222 in combination with a CFTR potentiator and a late binding CFTR corrector. GLPG2222 is an early binding CFTR corrector, and Kalydeco is a CFTR potentiator from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)...